Dme Capital Management, LP Roivant Sciences Ltd. Transaction History
Dme Capital Management, LP
- $1.97 Trillion
- Q1 2025
A detailed history of Dme Capital Management, LP transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Dme Capital Management, LP holds 5,441,167 shares of ROIV stock, worth $62.8 Million. This represents 2.78% of its overall portfolio holdings.
Number of Shares
5,441,167
Previous 5,271,067
3.23%
Holding current value
$62.8 Million
Previous $62.4 Billion
11.96%
% of portfolio
2.78%
Previous 3.21%
Shares
5 transactions
Others Institutions Holding ROIV
# of Institutions
349Shares Held
496MCall Options Held
3.67MPut Options Held
754K-
Qvt Financial LP New York, NY65.8MShares$760 Million69.8% of portfolio
-
Sb Investment Advisers (Uk) LTD London, X061.9MShares$714 Million5.69% of portfolio
-
Viking Global Investors LP46MShares$531 Million1.55% of portfolio
-
Vanguard Group Inc Valley Forge, PA40.8MShares$471 Million0.01% of portfolio
-
Morgan Stanley New York, NY35.9MShares$415 Million0.03% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $8.14B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...